Variant · Snv
ALK R1192P
CI-VAR-00003629Explore in graph →NP_004295.2:p.Arg1192ProNM_004304.4:c.3575G>CClinVar 18085 CIViC 1661 rs113994089
Curated evidence
Evidence by cancer (9 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27009859
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Large Cell Carcinoma1 | ||||||||
| ALK R1192P | Crizotinib | Predictive | D | Supports Resistance | — | submitted | EID4795In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK R1192P co-mutation, demonstrated resistance to crizotinib treatment (IC50: 421.5 … (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC | civic |
| Malignant Neoplasm6 | ||||||||
| EML4::ALK Fusion AND ALK R1192P | Alectinib | Predictive | D | Does Not Support Resistance | 2 | submitted | EID12667In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK R1192P co-mutation, demonstrated similar sensitivity to alectinib treatment (IC50: … (full text at CIViC) PMID · | |
ClinVar
Clinical significance (1)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
- Source
- NCBI ClinVar (variant_summary)
- Dataset
- ClinVar variant_summary
- Version
- 2026-09-06
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- database
- License
- Public domain (US Government work, NCBI/NLM); acknowledgment requested
- Run
- ING-CLINVAR-20260908-000001
| Variation | Clinical significance | Review status | Stars | Conditions | Origin | Submitters | Last evaluated | Source |
|---|---|---|---|---|---|---|---|---|
| 18085 | Pathogenic | criteria provided, single submitter | 1 | Neuroblastoma, susceptibility to, 3 | germline | 3 | Sep 29, 2021 | clinvar |